Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Inclusion Criteria:

- Is ≥ 40 kg and ≤ 125 kg.

- Documented CHC genotype 1 with HCV RNA ≥10,000 International Units (IU)/mL

- Has IL-28B CC allele gene

- Has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma
(non-invasive fibroscan and Fibrotest can also be used for staging of liver disease).

Exclusion Criteria:

- Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus
(Hepatitis B surface antigen [HBsAg] or HIV positive).

- Previously treated with an interferon and ribavirin regimen or HCV direct acting
antiviral regimen.

- Treatment for hepatitis C with any investigational medication, or prior treatments
with herbal remedies with known hepatotoxicity

- Receiving any medication(s) within 2 weeks prior to the Day 1 visit that are highly
dependent on Cytochrome P450 3A4 (CYP3A4/5) for clearance, and for which elevated
plasma concentrations could be associated with serious and/or life-threatening events

- Participation in any other clinical trial within 30 days of the screening visit in
this trial or intention to participate in another clinical trial during participation
in this trial.

- Evidence of decompensated liver disease or hepatocellular carcinoma (HCC)

- Is diabetic and/or hypertensive with significant retinopathy

- Has any known medical condition that could interfere with the participation in and
completion of the trial including immunologically-mediated disease, chronic pulmonary
disease, or current or history of any clinically significant cardiac
abnormalities/dysfunction.

- Evidence of active or suspected malignancy, or a history of malignancy, within the
last 5 years

- Hemoglobin <12 g/dL for females and <13 g/dL for males

- Neutrophils <1,500/mm^3, or <1,200/mm^3 for participants of African descent

- Platelets <150,000/mm^3

- Direct bilirubin >1.5 x upper limit of normal (ULN) of the laboratory reference
range.